• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Reva launches Fantom Encore bioresorbable scaffold

November 1, 2018 By Sarah Faulkner

Reva MedicalReva Medical (ASX:RVA) said this week that it launched its Fantom Encore bioresorbable, drug-eluting scaffold and that the first person was treated in a post-market trial of the device.

The Fantom Encore product is a third-gen coronary bioresorbable scaffold featuring a thin strut profile and Reva’s Tyrocore polymer.

Reva noted that the device will be made immediately available in Germany, Switzerland, Austria, Belgium, the Netherlands, Luxembourg, Italy and Turkey.

The Fantom post-market trial is slated to enroll 1,500 patients and is designed to assess the continued safety and efficacy of the Fantom and Fantom Encore products. The trial’s primary endpoint is target lesion failure after 12 months. Researchers plan to follow study participants through five years.

“My experience with Fantom Encore is that it is easy to use due to its thinner strut profile, x-ray visibility, and strength,” Dr. Matthias Lutz, co-principal investigator of the Fantom post-market trial, said in prepared remarks. “With these device improvements and the investment in the Fantom Post Market Trial, Reva is partnering with physicians to advance the field of bioresorbable scaffolds.”

“The commercial launch of Fantom Encore solidifies Reva’s technological lead in bioresorbable scaffolds,” CEO Reggie Groves added. “No other company has a thin strut profile, x-ray visible BRS. With a leading product and clinical data generated through the Fantom clinical trials, we are positioned for success in the coronary BRS market.”

Want to stay on top of DDBN content? Sign up for our e-mail newsletter for a weekly dose of drug-device news.

Filed Under: Drug-Device Combinations, Featured, Pharmaceuticals, Vascular, Wall Street Beat Tagged With: Reva Medical

IN CASE YOU MISSED IT

  • Medtronic to separate Diabetes business unit
  • Tandem Diabetes Care wins CE mark for Mobi insulin pump with Control-IQ+ technology
  • Glooko adds chief strategy officer to chief medical officer’s title
  • Cordis launches 10,000-patient registry for drug-eluting balloon
  • Senseonics opens $50M public offering, $25M private placement with Abbott

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS